Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Duloxetine for Prevention of Postherpetic Neuralgia
NCT04313335Completed
- Sponsor
- Beijing Tiantan Hospital
- Start
- Mar 2021
- Primary completion
- May 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, single-blind trial of duloxetine in postherpetic neuralgia (PHN) (2 arms), sponsored by Beijing Tiantan Hospital. Primary endpoint: Preventive efficacy of Postherpetic neuralgia at 12 weeks. Started Mar 2021; status: completed.
02
Drugs
duloxetine
03
Conditions
postherpetic neuralgia (PHN)
Beyond the preview
Go deeper on NCT04313335.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04313335.